Status:
COMPLETED
Effect of H2 Receptor Antagonist and Proton Pump Inhibitor on the Positivity Rates and Clinical Outcomes of COVID-19
Lead Sponsor:
Seoul National University Hospital
Collaborating Sponsors:
Dong-A ST Co., Ltd.
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
This retrospective cohort study aims to evaluate the effect of proton pump inhibitor (PPI) or histamine-2 receptor antagonist (H2RA) on the clinical outcomes and positivity rates of Coronavirus Diseas...
Detailed Description
Previous researches on the association between the use of PPI and H2RA and the treatment and prevention of COVID-19 have reported inconsistent findings. This study aimed to evaluate the effect of H2 r...
Eligibility Criteria
Inclusion
- Individuals who were tested for COVID-19 using real-time reverse transcriptase PCR assay of nasal and pharyngeal swabs
Exclusion
- Record of a new prescription of non-steroidal anti-inflammatory drugs (NSAID) within 1 month of the test date
- Patients who died within 48 hours after test.
Key Trial Info
Start Date :
May 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
400000 Patients enrolled
Trial Details
Trial ID
NCT04834752
Start Date
May 1 2021
End Date
December 31 2021
Last Update
November 29 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea, 03080